MP37-01 PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN PHEOCHROMOCYTOMA

Abstract

You have accessJournal of UrologyAdrenal1 Apr 2017MP37-01 PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN PHEOCHROMOCYTOMA Yasuhiro Hashimoto, Atsushi Imai, Shingo Hatakeyama, Takahiro Yoneyama, Takuya Koie, and Chikara Ohyama Yasuhiro HashimotoYasuhiro Hashimoto More articles by this author , Atsushi ImaiAtsushi Imai More articles by this author , Shingo HatakeyamaShingo Hatakeyama More articles by this author , Takahiro YoneyamaTakahiro Yoneyama More articles by this author , Takuya KoieTakuya Koie More articles by this author , and Chikara OhyamaChikara Ohyama More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.1133AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Programmed death ligand-1 (PD-L1), a key target molecule for immunotherapy, is frequently overexpressed in several neoplasms. In the present study, we examined PD-L1 expression in pheochromocytoma because very few reports on this subject are available. METHODS PD-L1 mRNA expression was compared across 184 pheochromocytoma, 492 prostate cancer, and 404 bladder cancer cases based on The Cancer Genome Atlas (TCGA). Furthermore, we enrolled 32 pheochromocytoma patients who were surgically treated at our hospital between June 2005 and February 2016. We conducted PD-L1 immunohistochemistry (IHC) using the SP142 assay. PD-L1 expression was scored at three diagnostic levels (0, 1, and 2). RESULTS A comparison of PD-L1 mRNA expression based on the TCGA revealed that PD-L1 expression was significantly higher in pheochromocytoma than in bladder cancer and prostate cancer (p < 0.001). The SP142 assay of our 32 surgical pheochromocytoma cases revealed that the prevalence of a PD-L1(+) expression (IHC score 1 or 2) in tumor-infiltrating immune cells (TICs) was 25% (eight patients) and that in tumor cells (TCs) was 28.1% (nine patients). The tumor diameter was significantly different between PD-L1(+) TIC patients (3.36 ± 0.35 cm) and PD-L1(-) TC patients (5.37 ± 0.50 cm, non-paired t-test: p = 0.044). In our cohort, there were two cases of malignant pheochromocytomas but none of them were PD-L1(+). CONCLUSIONS PD-L1 expression is relatively higher in pheochromocytoma than that in bladder cancer and prostate cancer based on TCGA. The SP142 assay of our 32 surgical pheochromocytoma cases revealed that the tumor diameter in PD-L1(-) TIC cases was larger than that in PD-L1(+) cases. Further, there were no PD-L1(+) cases of malignant pheochromocytoma. These findings suggest that PD-L1 expression in pheochromocytoma is relatively common and that PD-L1(+) expression in pheochromocytoma may not be associated with tumor aggressiveness. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e474 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Yasuhiro Hashimoto More articles by this author Atsushi Imai More articles by this author Shingo Hatakeyama More articles by this author Takahiro Yoneyama More articles by this author Takuya Koie More articles by this author Chikara Ohyama More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...